CX3, linked to defective HRR, was most frequent in high-risk non-MYCN-amplified patients (p < 2.1 × 10−2), further corroborating the role of deficient HRR as a risk-group-defining mutational process in neuroblastoma. This evidence concerns the gene MYCN and neuroblastoma.